MLYS vs. VERV, CVAC, OLMA, ATXS, KRRO, PHAT, NUVB, LYEL, GHRS, and ANAB
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Verve Therapeutics (VERV), CureVac (CVAC), Olema Pharmaceuticals (OLMA), Astria Therapeutics (ATXS), Korro Bio (KRRO), Phathom Pharmaceuticals (PHAT), Nuvation Bio (NUVB), Lyell Immunopharma (LYEL), GH Research (GHRS), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical preparations" industry.
Mineralys Therapeutics (NASDAQ:MLYS) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Mineralys Therapeutics has higher earnings, but lower revenue than Verve Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mineralys Therapeutics has a net margin of 0.00% compared to Verve Therapeutics' net margin of -1,701.70%. Mineralys Therapeutics' return on equity of -26.48% beat Verve Therapeutics' return on equity.
Mineralys Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500.
Verve Therapeutics received 7 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 44.74% of users gave Verve Therapeutics an outperform vote.
In the previous week, Verve Therapeutics had 4 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 4 mentions for Verve Therapeutics and 0 mentions for Mineralys Therapeutics. Verve Therapeutics' average media sentiment score of 0.64 beat Mineralys Therapeutics' score of 0.59 indicating that Verve Therapeutics is being referred to more favorably in the news media.
Mineralys Therapeutics presently has a consensus target price of $33.50, suggesting a potential upside of 203.44%. Verve Therapeutics has a consensus target price of $33.00, suggesting a potential upside of 430.55%. Given Verve Therapeutics' higher probable upside, analysts plainly believe Verve Therapeutics is more favorable than Mineralys Therapeutics.
84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are held by institutional investors. 21.4% of Verve Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Verve Therapeutics beats Mineralys Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
